STOP-PASC:  A Long-COVID Treatment Research Study

  • Stanford researchers are studying PAXLOVID (a drug that works against the COVID-19 virus) to treat Long-COVID.
  • The participant must have more than three months of Long COVID symptoms.
  • The participant will have a two-thirds (2/3) chance of being selected to receive PAXLOVID and one third (1/3) chance to receive a placebo (inactive drug).
  • There are 5 in-person visits to the Stanford area in Palo Alto, California.

Participating in the study is voluntary. This survey is also voluntary; you do not have to answer  any question on the form if you do not want to. Your information from this survey will only be seen by the study team and will be stored securely.

Please complete this information about yourself if you are interested in participating in the study or want to learn more.

Loading... Loading...
You have selected an option that triggers this survey to end right now.
To save your responses and end the survey, click the 'End Survey' button below. If you have selected the wrong option by accident and/or wish to return to the survey, click the 'Return and Edit Response' button.